Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Cephalon Likely To Launch In-House Actiq Generic To Compete With Barr

This article was originally published in The Pink Sheet Daily

  • News
  • Lee Kalowski

Executive Summary

Cephalon is planning to launch an in-house generic version of Actiq (transmucosal fentanyl) to compete with Barr, the company said

You may also be interested in...



See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On

Barr reports plans to begin selling a generic version of the pain drug in the second half of September.

See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On

Barr reports plans to begin selling a generic version of the pain drug in the second half of September.

Cephalon Anticipates Fentora Launch In Q4

Company also looking at 2007 launch for Nuvigil.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS061753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By